TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs

Alexey V. Seregin; Nadezhda E. Yun; Allison L. Poussard; Bi Hung Peng; Jennifer K. Smith; Jeanon N. Smith; Milagros Salazar; Slobodan Paessler

doi:10.1016/j.vaccine.2010.04.077

TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs

Alexey V. Seregin, Nadezhda E. Yun, Allison L. Poussard, Bi Hung Peng, Jennifer K. Smith, Jeanon N. Smith, Milagros Salazar, Slobodan Paessler

Pathology

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.

Original language	English (US)
Pages (from-to)	4713-4718
Number of pages	6
Journal	Vaccine
Volume	28
Issue number	30
DOIs	https://doi.org/10.1016/j.vaccine.2010.04.077
State	Published - Jul 2010

Keywords

Animal models
Hemorrhagic fever
Immune response
Reemerging pathogens
Vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.04.077

Cite this

@article{f1a71a3a00684e1098c58e9db20f3ce3,

title = "TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs",

abstract = "Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.",

keywords = "Animal models, Hemorrhagic fever, Immune response, Reemerging pathogens, Vaccine",

author = "Seregin, {Alexey V.} and Yun, {Nadezhda E.} and Poussard, {Allison L.} and Peng, {Bi Hung} and Smith, {Jennifer K.} and Smith, {Jeanon N.} and Milagros Salazar and Slobodan Paessler",

year = "2010",

month = jul,

doi = "10.1016/j.vaccine.2010.04.077",

language = "English (US)",

volume = "28",

pages = "4713--4718",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "30",

}

TY - JOUR

T1 - TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs

AU - Seregin, Alexey V.

AU - Yun, Nadezhda E.

AU - Poussard, Allison L.

AU - Peng, Bi Hung

AU - Smith, Jennifer K.

AU - Smith, Jeanon N.

AU - Salazar, Milagros

AU - Paessler, Slobodan

PY - 2010/7

Y1 - 2010/7

N2 - Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.

AB - Junin virus (JUNV) is the etiological agent of the potentially lethal, reemerging human disease, Argentine hemorrhagic fever (AHF). The mechanism of the disease development is not well understood and no antiviral therapy is available. Candid 1, a live-attenuated vaccine, has been developed by the US Army and is being used in the endemic area to prevent AHF. This vaccine is only approved for use in Argentina. In this study we have used the alphavirus-based approach to engineer a replicon system based on a human (United States Food and Drug Administration Investigational New Drug status) vaccine TC83 that express heterologous viral antigens, such as glycoproteins (GPC) of Junin virus (JUNV). Preclinical studies testing the immunogenicity and efficacy of TC83/GPC were performed in guinea pigs. A single dose of the live-attenuated alphavirus based vaccine expressing only GPC was immunogenic and provided partial protection, while a double dose of the same vaccine provided a complete protection against JUNV. This is the first scientific report to our knowledge that the immune response against GPC alone is sufficient to prevent lethal disease against JUNV in an animal model.

KW - Animal models

KW - Hemorrhagic fever

KW - Immune response

KW - Reemerging pathogens

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77954214468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954214468&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.04.077

DO - 10.1016/j.vaccine.2010.04.077

M3 - Article

C2 - 20452431

AN - SCOPUS:77954214468

SN - 0264-410X

VL - 28

SP - 4713

EP - 4718

JO - Vaccine

JF - Vaccine

IS - 30

ER -

TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this